NASDAQ:ALDX

Aldeyra Therapeutics (ALDX) Stock Forecast, Price & News

$5.53

-0.33 (-5.63%)

(As of 03:04 PM ET)

Compare

Today's Range: $5.53
▼
$5.84
50-Day Range: $5.86
▼
$8.12
52-Week Range: $4.95
▼
$11.97

Volume: 490,736 shs
Average Volume: 835,217 shs
Market Capitalization: $324.06 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.00

Aldeyra Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 239.9% Upside
$19.00 Price Target
Short Interest: Bearish
11.46% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.35
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.08) to ($1.24) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.68 out of 5 stars

Medical Sector

861st out of 966 stocks

Pharmaceutical Preparations Industry

401st out of 445 stocks

3.5

Analyst's Opinion

Consensus Rating
Aldeyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.00, Aldeyra Therapeutics has a forecasted upside of 239.9% from its current price of $5.59.
Amount of Analyst Coverage
Aldeyra Therapeutics has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
11.46% of the float of Aldeyra Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Aldeyra Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.
Change versus previous month
Short interest in Aldeyra Therapeutics has recently increased by 5.91%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aldeyra Therapeutics does not currently pay a dividend.
Dividend Growth
Aldeyra Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALDX.

3.0

News and Social Media Coverage

News Sentiment
Aldeyra Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Aldeyra Therapeutics this week, compared to 2 articles on an average week.
Search Interest
13 people have searched for ALDX on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.
MarketBeat Follows
3 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aldeyra Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.30% of the stock of Aldeyra Therapeutics is held by insiders.
Percentage Held by Institutions
66.62% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Aldeyra Therapeutics are expected to decrease in the coming year, from ($1.08) to ($1.24) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aldeyra Therapeutics is -6.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aldeyra Therapeutics is -6.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aldeyra Therapeutics has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aldeyra Therapeutics (NASDAQ:ALDX) Stock

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

ALDX Price History

30 days | 90 days | 365 days | Advanced Chart

ALDX Stock News Headlines

September 29, 2023 | markets.businessinsider.com

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses to Contact the Firm

September 28, 2023 | stockhouse.com

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

October 4, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

September 28, 2023 | tmcnet.com

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)

September 26, 2023 | businesswire.com

Deadline Alert: ALDX Investor Alert: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Aldeyra Therapeutics, Inc. Class Action Lawsuit

September 26, 2023 | americanbankingnews.com

Aldeyra Therapeutics (NASDAQ:ALDX) Share Price Crosses Below 50 Day Moving Average of $7.42

September 25, 2023 | stockhouse.com

FRIDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

September 24, 2023 | prnewswire.com

ALDX FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX

October 4, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

September 18, 2023 | msn.com

Eyeing Returns: Aldeyra's Shift From Lab To Market

September 15, 2023 | finance.yahoo.com

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has caught the attention of institutional investors who hold a sizeable 43% stake

September 11, 2023 | stockhouse.com

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

September 6, 2023 | stockhouse.com

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

August 31, 2023 | businesswire.com

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ...

August 24, 2023 | benzinga.com

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc. (ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline

August 24, 2023 | benzinga.com

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline

August 21, 2023 | benzinga.com

ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit

August 18, 2023 | stockhouse.com

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

August 17, 2023 | stockhouse.com

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

August 14, 2023 | stockhouse.com

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

August 12, 2023 | benzinga.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action Against Aldeyra Therapeutics, Inc. and Certain Officers – ALDX

August 11, 2023 | prnewswire.com

ROSEN, A TOP RANKED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

August 11, 2023 | benzinga.com

ALDX Stock News: Shareholders with Significant Losses in Aldeyra Therapeutics, Inc. Should Contact Robbins LLP

August 11, 2023 | benzinga.com

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)

August 11, 2023 | businesswire.com

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)

August 10, 2023 | msn.com

Oppenheimer Reiterates Aldeyra Therapeutics (ALDX) Outperform Recommendation

August 9, 2023 | markets.businessinsider.com

Expert Ratings for Aldeyra Therapeutics

See More Headlines

Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALDX Company Calendar

Last Earnings: 8/03/2023
Today: 10/04/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALDX
CUSIP: N/A
CIK: 1341235
Web: www.ampliphibio.com
Phone: 781-761-4904
Fax: 781-270-0630
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $19.00
High Stock Price Forecast: $28.00
Low Stock Price Forecast: $14.00
Forecasted Upside/Downside: +233.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-62,030,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -35.88%
Return on Assets: -29.97%

Debt

Debt-to-Equity Ratio: 0.08
Current Ratio: 9.96
Quick Ratio: 9.96

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.58 per share
Price / Book: 2.21

Miscellaneous

Outstanding Shares: 58,600,000
Free Float: 54,318,000
Market Cap: $334.02 million
Optionable: Optionable
Beta: 1.10

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Todd C. Brady (Age 48)
M.D., Ph.D., Chief Executive Officer and Director

Joshua Reed (Age 47)
Chief Financial Officer

David McMullin (Age 45)
Chief Commercial Officer

James A. Gow (Age 53)
M.D., Senior Vice President of Clinical Development

Stephen G. Machatha (Age 43)
Ph.D., Senior Vice President, Technical Operation

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ALDX Stock - Frequently Asked Questions

Should I buy or sell Aldeyra Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALDX shares.
View ALDX analyst ratings or view top-rated stocks.
What is Aldeyra Therapeutics' stock price forecast for 2023?: 2 equities research analysts have issued 1 year target prices for Aldeyra Therapeutics' stock. Their ALDX share price forecasts range from $14.00 to $28.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price.
View analysts price targets for ALDX or view top-rated stocks among Wall Street analysts.
How have ALDX shares performed in 2023?: Aldeyra Therapeutics' stock was trading at $6.96 at the start of the year. Since then, ALDX shares have decreased by 18.1% and is now trading at $5.70.
View the best growth stocks for 2023 here.
Are investors shorting Aldeyra Therapeutics?: Aldeyra Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 6,450,000 shares, an increase of 5.9% from the August 31st total of 6,090,000 shares. Based on an average daily volume of 646,300 shares, the short-interest ratio is presently 10.0 days. Currently, 11.5% of the company's stock are sold short.
View Aldeyra Therapeutics' Short Interest.
When is Aldeyra Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ALDX earnings forecast.
How were Aldeyra Therapeutics' earnings last quarter?: Aldeyra Therapeutics, Inc (NASDAQ:ALDX) released its quarterly earnings data on Thursday, August, 3rd. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.16.

What ETF holds Aldeyra Therapeutics' stock ?: Invesco Dorsey Wright Healthcare Momentum ETF holds 172,465 shares of ALDX stock, representing 0.81% of its portfolio.
What other stocks do shareholders of Aldeyra Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).
What is Aldeyra Therapeutics' stock symbol?: Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."
How do I buy shares of Aldeyra Therapeutics?: Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aldeyra Therapeutics' stock price today?: One share of ALDX stock can currently be purchased for approximately $5.70.
How much money does Aldeyra Therapeutics make?: Aldeyra Therapeutics (NASDAQ:ALDX) has a market capitalization of $334.02 million. The biotechnology company earns $-62,030,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.
How can I contact Aldeyra Therapeutics?: Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The official website for the company is www.ampliphibio.com. The biotechnology company can be reached via phone at 781-761-4904, via email at ir@ampliphibio.com, or via fax at 781-270-0630.

This page (NASDAQ:ALDX) was last updated on 10/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial